Meeting
2020 ASCO Virtual Scientific Program
Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder.
Authors
Amarnath Challapalli
University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom
Amarnath Challapalli , Susan Masson , Paul White , Narges Dailami , Sylvia Pearson , Edward Rowe , Anthony Koupparis , Jon Oxley , Janice Ash-Miles , Alicia Bravo , Emily Foulstone , Raj Persad , Amit Bahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
2011 004090 82
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5030)
DOI
10.1200/JCO.2020.38.15_suppl.5030
Abstract #
5030
Poster Bd #
99
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2023 ASCO Annual Meeting
Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.
First Author: Anumita Chakraborty
Poster
2023 ASCO Genitourinary Cancers Symposium
Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
First Author: Ahsan Ayaz
Poster
2023 ASCO Genitourinary Cancers Symposium
Radical radiotherapy for muscle-invasive bladder cancer: A single centre experience.
First Author: Mayumi Forster